
Cancer Research UK and ORIC partner on CIP2A-targeted therapy
Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More
